Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|February 13, 2019
Inhalation Formulation of Itraconazole Receives IND Authorization From FDA
Author(s)Michaela Fleming
The FDA has authorized a phase 2 study of PUR1900, an inhaled formulation of itraconazole, for the treatment of allergic bronchopulmonary aspergillosis.
Advertisement
The US Food and Drug Administration (FDA) has approved an Investigational New Drug application for PUR1900 (Pulmazole), an inhaled formulation of itraconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma.
The antifungal drug is being developed by Pulmatrix, Inc., which also announced that the FDA has authorized the initiation of a phase 2 clinical trial.
Allergic bronchopulmonary aspergillosis commonly occurs in individuals with asthma or cystic fibrosis, can include an allergic hypersensitivity response of the immune system to Aspergillus colonization and growth in the airways.
Oral itraconazole (Sporanox) is currently used as a treatment alongside corticosteroids in allergic bronchopulmonary aspergillosis patients. However, its use is limited by “poor bioavailability, variable pharmacokinetics, and toxicity concerns related primarily to the risk of gastrointestinal and cardiac side effects, as well as extensive drug-drug interactions.”
According to the announcement by Pulmatrix, the trial will be initiated in the first half of 2019 and will be a randomized, double-blind, multicenter, placebo-controlled study. The trial will evaluate the safety, tolerability, and pharmacokinetics of the antifungal itraconazole administered as a dry powder for inhalation.
A total of 46 participants include adult patients with asthma and allergic bronchopulmonary aspergillosis. The participants will be randomly assigned (1:1:1:1) into 4 treatment arms at the point of enrollment. In the respective treatment arms, participants will receive 10 mg, 20 mg, or 35 mg of PUR1900 or placebo, administered via once daily dry powder inhalation daily for 28 days.
While the primary objective of the study is to evaluate the safety and tolerability of multiple doses of PUR1900, secondary objectives will include the characterization of pharmacokinetics of inhaled PUR1900 in plasma and sputum and the effect of the study drug on inflammation, pulmonary function, asthma symptoms, and Aspergillus burden in sputum.
"We are very pleased that the FDA review of the IND is complete allowing us to proceed and this important regulatory milestone reinforces Pulmatrix's intention to bring an improved novel therapeutic option to patients suffering from ABPA. This is a critical step in the progression of Pulmazole to bring the product to patients in the US," Robert Clarke, PhD, chief executive officer of Pulmatrix, said in a
PUR1900 is the first inhaled dry powder version of itraconazole. The drug is being developed with the goal of improving upon the safety and efficacy profile associated with oral Sporanox by delivering the drug directly to the lung.
Top line data is expected in the second quarter of 2020.
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.